Brinzolamide is a carbonic anhydrase inhibitor used to treat glaucoma. However, during the manufacturing process, impurities can be formed. These impurities can affect the safety and efficacy of the drug. Therefore, it is necessary to identify and control these impurities to ensure the quality of the final product. Various analytical methods are used to detect and quantify Brinzolamide impurities, including HPLC, GC, and LC-MS.
